Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Laura S van Dam"'
Autor:
Cees van Kooten, Y K Onno Teng, Willem Jan Bos, Obbo W Bredewold, Argho Ray, Jacqueline T Jonker, Hilde H F Remmelts, Ebru Dirikgil, Jolijn R van Leeuwen, Darius Soonawala, Bastiaan van Dam, Joris Rotmans, Ton Rabelink, Laura S van Dam
Publikováno v:
BMJ Open, Vol 12, Iss 9 (2022)
Introduction Both rituximab (RTX) and cyclophosphamide (CYC) are effectively used in combination with steroids as remission induction therapy for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Several studies ha
Externí odkaz:
https://doaj.org/article/93e10e71ff174e9784e45f43637e181b
Autor:
Jolijn R. van Leeuwen, Obbo W. Bredewold, Laura S. van Dam, Stella L. Werkman, Jacqueline T. Jonker, Miranda Geelhoed, Antonius P.M. Langeveld, Hilde H.F. Remmelts, Maud M. van den Broecke, Argho Ray, Ton J. Rabelink, Y.K. Onno Teng
Publikováno v:
Kidney International Reports, Vol 7, Iss 3, Pp 624-628 (2022)
Externí odkaz:
https://doaj.org/article/5b3fb8844ccb42a4b56ad3cfd673ea1b
Autor:
Laura S. van Dam, Jelle M. Oskam, Sylvia W. A. Kamerling, Eline J. Arends, O. W. Bredewold, Magdalena A. Berkowska, Jacques J. M. van Dongen, Ton J. Rabelink, Cees van Kooten, Y. K. Onno Teng
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
BackgroundB-cell depletion with rituximab (RTX) is an effective treatment for anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) patients. Nevertheless, relapses are frequent after RTX, often preceded by B-cell repopulation sug
Externí odkaz:
https://doaj.org/article/88a01c1caada4b079f0609fa32b551e0
Autor:
Ebru Dirikgil, Jolijn R van Leeuwen, Laura S van Dam, Obbo W Bredewold, Argho Ray, Jacqueline T Jonker, Darius Soonawala, Hilde H F Remmelts, Bastiaan van Dam, Willem Jan Bos, Cees van Kooten, Joris Rotmans, Ton Rabelink, Y K Onno Teng
Publikováno v:
BMJ Open, 12(9). BMJ PUBLISHING GROUP
IntroductionBoth rituximab (RTX) and cyclophosphamide (CYC) are effectively used in combination with steroids as remission induction therapy for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Several studies hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba516f06da3bc51c3c9c50e85bdb92a0
https://hdl.handle.net/1887/3563164
https://hdl.handle.net/1887/3563164
Autor:
Tom J.W. Huizinga, Tineke Kraaij, Y K Onno Teng, Obbo W. Bredewold, Argho Ray, Hans Scherer, Cees van Kooten, Sylvia W.A. Kamerling, E J Arends, Jaap A. Bakker, Laura S van Dam, Ton J. Rabelink, Paul L A van Daele
Publikováno v:
Nephrology Dialysis Transplantation, 36(8), 1474-1483. OXFORD UNIV PRESS
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association-European Renal Association, 36(8), 1474-1483. Oxford University Press
Nephrology Dialysis Transplantation
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association-European Renal Association, 36(8), 1474-1483. Oxford University Press
Nephrology Dialysis Transplantation
Background Anti-CD20 B-cell depletion has not shown superior efficacy to standard immunosuppression in patients with systemic lupus erythematosus (SLE). Besides trial design, potential explanations are incomplete B-cell depletion in relation to subst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3523d4f945aa15e9a2826159f3ad5da7
http://hdl.handle.net/1887/3249768
http://hdl.handle.net/1887/3249768
Publikováno v:
Kidney International Reports, Vol 4, Iss 2, Pp 196-211 (2019)
Kidney International Reports, 4(2), 196-211
Kidney International Reports
Kidney International Reports, 4(2), 196-211
Kidney International Reports
Neutrophil extracellular traps (NETs) are extracellular DNA structures covered with antimicrobial peptides, danger molecules, and autoantigens that can be released by neutrophils. NETs are an important first-line defense mechanism against bacterial,
Autor:
Jelle M Oskam, Jacques J.M. van Dongen, Y K Onno Teng, E J Arends, Magdalena A Berkowska, Obbo W. Bredewold, Cees van Kooten, Ton J. Rabelink, Laura S van Dam, Sylvia W.A. Kamerling
Publikováno v:
Frontiers in Immunology, 11. FRONTIERS MEDIA SA
Frontiers in Immunology, Vol 11 (2020)
Frontiers in Immunology
Frontiers in Immunology, Vol 11 (2020)
Frontiers in Immunology
BackgroundB-cell depletion with rituximab (RTX) is an effective treatment for anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) patients. Nevertheless, relapses are frequent after RTX, often preceded by B-cell repopulation sug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95bb34647ec256116e06c3d74c3214c7
https://hdl.handle.net/1887/3184295
https://hdl.handle.net/1887/3184295
Autor:
Zgjim Osmani, Laura S van Dam, Reinhard E. Voll, Ton J. Rabelink, Hans Scherer, David A. Isenberg, Cees van Kooten, Jaap A. Bakker, Sylvia W.A. Kamerling, Tineke Kraaij, Y K Onno Teng, Tobias Alexander
Publikováno v:
Rheumatology (Oxford, England)
Rheumatology, 59(10), 2734-2745. OXFORD UNIV PRESS
Rheumatology, 59(10), 2734-2745. OXFORD UNIV PRESS
ObjectivesSLE is a severe autoimmune disease characterized by autoreactive B cells and IC formation, which causes systemic inflammation. B cell–targeted therapy could be a promising treatment strategy in SLE patients; nevertheless, randomized clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19ca8fbf6b43259f7c0671ef27d742b3
https://doi.org/10.1093/rheumatology/kez623
https://doi.org/10.1093/rheumatology/kez623
Autor:
Ton J. Rabelink, Tineke Kraaij, Sylvia W.A. Kamerling, Uli H Scherer, Y K Onno Teng, Laura S van Dam, Cees van Kooten, Jaap A. Bakker
Publikováno v:
Arthritis and Rheumatology
Arthritis & Rheumatology (Hoboken, N.j.)
Arthritis & Rheumatology (Hoboken, N.j.)
Objective Different studies have demonstrated that neutrophil extracellular traps (NETs) may be involved in the pathophysiology of both antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) and systemic lupus erythematosus (SLE). A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72efbe4253c467b68eef635bce3662af
https://hdl.handle.net/1887/120433
https://hdl.handle.net/1887/120433
Autor:
Max M. van Noesel, Friederike A.G. Meyer-Wentrup, Anke E M van Erp, Laura S van Dam, Uta Flucke, Laurens van Houdt, Mark A.J. Gorris, Thomas Mentzel, Janet Shipley, Yvonne M.H. Versleijen-Jonkers, Marije E. Weidema, Winette T. A. van der Graaf, Melissa H.S. Hillebrandt-Roeffen, C. Dilara Savci-Heijink, Hans H.M. Merks, Ingrid M.E. Desar
Publikováno v:
Oncotarget, 8(41), 71371-71384. Impact Journals
Oncotarget, 8, 71371-71384
Oncotarget, 8, 41, pp. 71371-71384
Oncotarget, 8, 71371-71384
Oncotarget, 8, 41, pp. 71371-71384
Contains fulltext : 181907.pdf (Publisher’s version ) (Open Access) In order to explore the potential of immune checkpoint blockade in sarcoma, we investigated expression and clinical relevance of programmed cell death-1 (PD-1), programmed death li